We are live on ! Find out more
MAIA icon

MAIA Biotechnology
MAIA

26 hedge funds and large institutions have $4.09M invested in MAIA Biotechnology in 2025 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

37% more funds holding

Funds holding: 19 → 26 (+7)

17% more capital invested

Capital invested by funds: $3.49M → $4.09M (+$604K)

0.4% less ownership

Funds ownership: 7.19% → 6.8% (-0.4%)

Holders
26
Holders Change
+7
Holders Change %
+36.84%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
8
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
+$103K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$67.5K
3
Creative Planning
Creative Planning
Kansas
+$37.6K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$33.5K
5
RWM
Ritholtz Wealth Management
New York
+$30.1K

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$170K
2
TRCT
Tower Research Capital (TRC)
New York
-$6.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.77M +$67.5K +51,688 +5%
CWM
2
Centric Wealth Management
Illinois
$1.14M +$15K +11,500 +2%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$454K +$33.5K +25,684 +9%
BlackRock
4
BlackRock
New York
$164K +$3.12K +2,388 +2%
Jane Street
5
Jane Street
New York
$120K +$103K +78,757 New
State Street
6
State Street
Massachusetts
$116K – – –
Northern Trust
7
Northern Trust
Illinois
$59.7K – – –
BCM
8
Bridgeway Capital Management
Texas
$55.1K – – –
Creative Planning
9
Creative Planning
Kansas
$44.1K +$37.6K +28,822 New
RWM
10
Ritholtz Wealth Management
New York
$35.3K +$30.1K +23,071 New
CAG
11
Centerpoint Advisory Group
Kansas
$24.1K – – –
Wealth Enhancement Advisory Services
12
Wealth Enhancement Advisory Services
Minnesota
$22.6K – – –
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$21.9K +$3.49K +2,673 +23%
Cambridge Investment Research Advisors
14
Cambridge Investment Research Advisors
Iowa
$16K +$13.9K +10,620 New
SG
15
StoneX Group
New York
$15.7K +$13.4K +10,249 New
Osaic Holdings
16
Osaic Holdings
Arizona
$12.8K – – –
DSC
17
Daytona Street Capital
Missouri
$11.5K +$9.79K +7,500 New
UBS Group
18
UBS Group
Switzerland
$3.32K +$2.83K +2,170 New
CW
19
Curio Wealth
Maryland
$2.96K – – –
Citigroup
20
Citigroup
New York
$2.66K +$1.58K +1,208 +228%
Morgan Stanley
21
Morgan Stanley
New York
$1.53K +$219 +168 +20%
MCM
22
MAI Capital Management
Ohio
$1.03K – – –
SA
23
SRH Advisors
Kansas
$999 +$852 +653 New
TAM
24
Tucker Asset Management
Colorado
$522 +$445 +341 New
Jones Financial Companies
25
Jones Financial Companies
Missouri
$349 – – –
1
2

MAIA Hedge Fund Activity: Q4 2025 in Review

26 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in MAIA Biotechnology (MAIA) for Q4 2025, worth a combined $4.09M — up 17% from $3.49M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new MAIA positions and 2 closed out — a net gain of 7 holders — while 8 added to existing stakes and 0 trimmed.

The largest buyer was Jane Street, opening a new position worth an estimated $103K. The largest seller was Marshall Wace, exiting entirely with an estimated $170K sold.

  • 26 institutional investors held MAIA Biotechnology (MAIA) as of Q4 2025, up from 19 in Q3 2025.
  • Funds reported $4.09M of MAIA Biotechnology stock for Q4 2025, up 17% quarter-over-quarter.
  • 9 funds opened new MAIA Biotechnology positions in Q4 2025 and 2 closed out, a net change of +7 holders.
  • The largest MAIA Biotechnology buyer in Q4 2025 was Jane Street, an estimated $103K added.
  • The largest MAIA Biotechnology seller in Q4 2025 was Marshall Wace, an estimated $170K sold.

Based on aggregated 13F filings for Q4 2025.